Urol. praxi. 2016;17(2):64-68 | DOI: 10.36290/uro.2016.017

Current position of chemotherapy in treating bladder cancer

MUDr.Jana Katolická, Ph.D.
Onkologicko-chirurgické oddělení, FN u svaté Anny v Brně

Chemotherapy in treating bladder cancer is used in all clinical stages. Its administration is indicated according to the European

Association of Urology guidelines in both non-invasive forms (A) and neoadjuvant (1a) and adjuvant (A) in the case of clinical

trials and for patients with positive nodes without neoadjuvant therapy (C) administration in invasive tumours. It has a clear role

in treating patients with metastatic disease (1b) both for the cisplatin-based first line and for vinflunine in the second line. Immunotherapy

brings new treatment options for metastatic urothelial carcinoma of the urinary bladder.

Keywords: intravesical chemotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy, palliative chemotherapy, immunotherapy

Published: April 23, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Current position of chemotherapy in treating bladder cancer. Urol. praxi. 2016;17(2):64-68. doi: 10.36290/uro.2016.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Madersbacher S, Hochreiter W, Burkhard F. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21: 690-696. Go to original source... Go to PubMed...
    2. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, DePauw M. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995; 153: 934. Go to original source... Go to PubMed...
    3. Sylvester RJ, Oosterlinck W, van der Meijden APOD. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186. Go to original source... Go to PubMed...
    4. Vishnu P. Current therapeutic strategies for invasive and metastatic bladder cancer. OncoTargets and Therapy 2011; 4: 97-113. Go to original source... Go to PubMed...
    5. Raghavan D, Shipley WU, Garnick MMB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med. 1990; 322(16): 1129-1138. Go to original source... Go to PubMed...
    6. Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res. 2006; 12(1): 139-143. Go to original source... Go to PubMed...
    7. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354(9178): 533-540. Go to original source...
    8. Vogelzang NJ. Neoadjuvant MVAC: The long and winding road is getting shorter and straighter JCO 2001; 19: 4003-4004. Go to original source... Go to PubMed...
    9. Malstrom PU, Rintala E, Wahlquist R, Hellstron P, Hellsten S, Hannisdal E. Five-year follow up of prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial 1. The Nordic Cooperative Bladder Cancer Study Group.J Urol 1996; 155(6): 1903-1906. Go to original source...
    10. Sherif A, Rintala E, Mestad O. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002; 36(6): 419-425. Go to original source... Go to PubMed...
    11. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. American Society of Clinical Oncology Annual Meeting; 1995, Philadelphia, PA.
    12. Vale CL. Meta-analysis Group MCTU, London, UK. Neoadjuvant chemotherapy in invasive bladder cancer:update of a systematic review and meta-analysis of individual patient dataadvanced bladder cancer (ABC)meta-analysis collaboration. Eur Urol. 2005; 48(2): 202-205; discussion 205-206. Go to PubMed...
    13. Griffiths G, Trialists. OboIco. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastin chemotherapy for muscle-invasive bladder cancer: long term results of the BA06 30894 Trial. J Clin Oncol. 2011. doi: 10.1200/JCO.2010.32.3139. Go to original source... Go to PubMed...
    14. Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N Engl J Med. 2003; 349(9): 859-866. Go to original source... Go to PubMed...
    15. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug; 48(2): 202-205; discussion 205-6. Epub 2005 Apr 21. Go to PubMed...
    16. Smith DC, Grivas P, Daignault S. A phase II trial of neoadjuvant ABI-007, carboplatine and gemcitabine (ACG) in patients with localy advanced carcinoma of bladder. American Society of Clinical Oncology Genitourinary cancer symposium;2011, Orlando, FL. Go to original source...
    17. Blick C, Hall P, Pwint T. Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of bladder. Cancer. 2012 Aug 15;118(16):3920-7. doi: 10.1002/cncr.26675. Epub 2012 Jan 3. Go to original source... Go to PubMed...
    18. Winquist E, Kirchner TS, Segal R. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004 Feb; 171(2 Pt 1): 561-569. Go to original source... Go to PubMed...
    19. EUA guidelines: Babjuk M, Bohle A, Burger M, Compérat E, Kaasinen, Palou J, va Rhijn BWG, Roupret M, Shariat S, Sylvester R, Zigeuner R. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS) uroweb.org.
    20. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebrét T, Ribal MJ, Sherif A, van der Heijden AG. Muscle-invasive and metastatic bladder cancer. Eur Urol 2014 Mar; 65(3): 778-92. Go to original source... Go to PubMed...
    21. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006; 176: 486-492 discussion 491-2. Go to original source... Go to PubMed...
    22. Vale CL. On behalf of Meta-analysis Group MCTU, London, UK. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 482(2): 189-199; discussion 199-201.
    23. Paz-Ares G, Solsona E, Esteban E. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer:results of the Spanish onkology Genitourinary Group (SOUGUG) 99/01 study. American Society of Clinical Oncology Annual Meeting; 2010. Chicago, IL. Go to original source...
    24. Sternberg CN, Yagoda A, Scher HI. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64(12): 2448-2458. Go to original source...
    25. Logothetis CJ, Dexeus FH, Finn L. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urotelial tumors. J Clin Oncol.1990; 8(6): 1050-1055. Go to original source... Go to PubMed...
    26. Sternberg CN, de Mulder PH, Schornagel JH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol. 2001; 19(10): 2638-2646. Go to original source... Go to PubMed...
    27. von der Maase H, Hansen SW, Roberts JT. Gemcitabine and cisplatine versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068-3077. Go to original source... Go to PubMed...
    28. Dreicer R, Manola J, Roth BJ. Phase III trial methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of urotelium. Cancer.2004; 100(8): 1639-1645. Go to original source... Go to PubMed...
    29. Hahn NM, Stadler WM, Zon R. Mature results from Hoosier Oncology Group GU 04-75 phase II trial of cisplatin (C), gemcitabine (G) and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Socienty of Clinical Oncology Annual Meeting:2010. Chicago,IL. Go to original source...
    30. Gallagher DJ, Milowsky MI, Gerst SR. Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (uc) [abstract 5082] J Clin Oncol. 2008; 26. Go to original source... Go to PubMed...
    31. Bellmunt J, Eigl BJ, Senkus-Konefka E, et al. First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. J Clin Oncol 2015; 33: (suppl; abstr 4503). Go to original source...
    32. Bellmunt J, Theodore C, Demkov Z. Phase III trial of vinflunine plus best supportive care compared with best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27(27): 4454-4461. Go to original source... Go to PubMed...
    33. Serrate C, Pouessel D, Gauthier H, le Maignan Ch, Teixeira L, Cilune S. Vinflinine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies. Clin.Invest. 2014; 4(4): 305-311.doi.10.4155/CLI.14.15 Go to original source...
    34. Tumeh PC, et al. PD 1 blockade induced responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571. Go to original source... Go to PubMed...
    35. Powels T, et al. Inhibition of PD-L1 by MPDL3280A and clinical aktivity in pts with metastatic urothelial bladder cancer. J Clin Oncol 2014; 32: 5s (Suppl: abstr 5011) Go to original source...
    36. O'Donnell PH, Plimack ER, et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer. Results of phase IB study. J Clin Oncol 2015; 33:(Suppl7; abstr 296). Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.